Fig. 1From: Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinomaNeutrophil-to-lymphocyte ratio (NLR) at start of anti-PD-1/PD-L1 therapy by a IMDC risk groups and b Histology (clear cell RCC, ccRCC; non-clear cell RCC, nccRCC)Back to article page